https://onlinelibrary.wiley.com/doi/pdf/10.1002/jps.2600600902

Pharmaceutical Applications of Solid Dispersion Systems

An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.

Analyte Monitoring Device And Methods Of Use

Purpose To evaluate the magnitude of the solubility advantage foramorphous pharmaceutical materials when compared to their crystallinecounterpartsMethods The thermal properties of several drugs in their amorphousand crystalline states were determined using differential scanningcalorimetry From these properties the solubility advantage for theamorphous form was predicted as a function of temperature using a simplethermodynamic analysis These predictions were compared to theresults of experimental measurements of the aqueous solubilities of theamorphous and crystalline forms of the drugs at several temperaturesResults By treating each amorphous drug as either an equilibriumsupercooled liquid or a pseudo-equilibrium glass, the solubilityadvantage compared to the most stable crystalline form was predicted to bebetween 10 and 1600 fold The measured solubility advantage wasusually considerably less than this, and for one compound studied indetail its temperature dependence was also less than predicted It wascalculated that even for partially amorphous materials the apparentsolubility enhancement (theoretical or measured) is likely to influencein-vitro and in-vivo dissolution behaviorConclusions Amorphous pharmaceuticals are markedly more solublethan their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simplethermodynamic considerations This appears to be the result of difficulties indetermining the solubility of amorphous materials under trueequilibrium conditions Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage foramorphous pharmaceuticals, which directly reflects the driving forcefor their initial dissolution

/pdf/what-is-the-true-solubility-advantage-for-amorphous-494qziae2i.pdf

What is the true solubility advantage for amorphous pharmaceuticals

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

Transcutaneous analyte sensor

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jps.2600580802

Pharmaceutical Applications of Polymorphism

Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation

Novobiocin (Cathomycin) is an antibiotic produced in nutrient media by Streptomyces spheroides . Physical characteristics of the amorphous acid form of novobiocin were studied. The amorphous acid is biologically active, but proved metastable in aqueous suspension, reverting on standing to a less soluble, inactive crystal line form. Several distinct steps were identified during the process of reversion; the rate of reversion was found to be temperature dependent. Methods for suppressing crystallization of the amorphous acid are discussed. The properties of amorphous calcium novobiocin in formulation of aqueous suspensions were studied.

John D Mullins

Papers

Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation

Some pharmaceutical properties of novobiocin.

Parenteral aqueous solutions of fat soluble vitamins

Suppression of amorphous novobiocin crystallization in aqueous suspensions